Bladder cancer is the 6th most common cancer in the USA, with over 81 thousand new cases annually. There are currently over 6.7 million patients with hematuria who need an accurate and non-invasive diagnostic test.
The current gold standard for bladder cancer detection is cystoscopy.
Cystoscopy is a painful and invasive procedure.
Confirmatory tests such as a CT scan, intravenous, pyelogram (IVP), X-Ray, MRI, ultra-sound, and urine cytology are also used but with limited utility.
These challenges are why Protean BioDiagnostics is excited to introduce the URO17 urine test for detecting bladder cancer. The URO17 test is is an immunocytochemical test based on a novel biomarker, with 100% sensitivity and 96% specificity* for detecting bladder cancer from urine samples.
Sensitive and Specific
The URO17 Urine test has 100% sensitivity & 96% specificity.*
Compatible
Works with all standard immunohistochemistry systems, and detects high grade and low grade bladder cancer.
Gold Standard Potential
Testing suggests that the URO17 test could improve accuracy of cytology and cystoscopy in monitoring recurrence cases, and detection of new cases in patients with hematuria.
How URO17 Compares with other Popular Urine Tests for Bladder Cancer
*Babu et. al., Modern Pathology, 2019 May; 32(5):717-724
Order a URO17 Collection Kit Today.
Fill out your contact information below, and we will reach out to you with next steps.
Questions about URO17?
Call us at: 1 (754) 242 9682 | Email us at: info@proteanbiodx.com
